专利检索 ap:("Merck Sharp & Dohme Corp.") AND inv:"Paul Carrington" 第 1 页

1.

发明授权
Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors 有权

公开(公告)号：US10800826B2

公开(公告)日：2020-10-13

申请号：US15765505

申请日：2016-10-04

申请人： Merck Sharp & Dohme Corp. , Ambrx, Inc.

发明人： Paul Carrington , Grigori Ermakov , Robert M. Garbaccio , Wolfgang Seghezzi , Elisabetta Bianchi , Federica Orvieto , Dennis Gately , Nick Knudsen , Anthony Manibusan

IPC分类号： C07K14/605 , C07K16/26 , C07K16/28 , A61K47/68 , A61P3/10 , A61K39/00

摘要： Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.

2.

发明申请
ANTIBODY PEPTIDE CONJUGATES THAT HAVE AGONIST ACTIVITY AT BOTH THE GLUCAGON AND GLUCAGON-LIKE PEPTIDE 1 RECEPTORS 审中-公开

公开(公告)号：US20190071483A1

公开(公告)日：2019-03-07

申请号：US15765505

申请日：2016-10-04

申请人： Merck Sharp & Dohme Corp.

发明人： Paul Carrington , Grigori Ermakov , Robert M. Garbaccio , Wolfgang Seghezzi , Elisabetta Bianchi , Federica Orvieto , Dennis Gately , Nick Knudsen , Anthony Manibusan

IPC分类号： C07K14/605 , A61K47/68 , C07K16/26 , C07K16/28 , A61P3/10

CPC分类号： C07K14/605 , A61K47/6811 , A61K47/6843 , A61K2039/505 , A61P3/10 , C07K16/26 , C07K16/2869 , C07K2317/75 , C07K2319/00

摘要： Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.